Grace Therapeutics Statistics
Total Valuation
GRCE has a market cap or net worth of $33.36 million. The enterprise value is $22.31 million.
Important Dates
The last earnings date was Thursday, February 13, 2025, before market open.
Earnings Date | Feb 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
GRCE has 10.14 million shares outstanding. The number of shares has increased by 34.86% in one year.
Current Share Class | 10.14M |
Shares Outstanding | 10.14M |
Shares Change (YoY) | +34.86% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 25.22% |
Owned by Institutions (%) | 7.85% |
Float | 5.23M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.64 |
P/TBV Ratio | 11.61 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.06
Current Ratio | 6.06 |
Quick Ratio | 5.76 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -22.89% and return on invested capital (ROIC) is -17.83%.
Return on Equity (ROE) | -22.89% |
Return on Assets (ROA) | -15.16% |
Return on Invested Capital (ROIC) | -17.83% |
Return on Capital Employed (ROCE) | -28.13% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | -3.07M |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | 1.37 |
52-Week Price Change | n/a |
50-Day Moving Average | 3.67 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 42.89 |
Average Volume (20 Days) | 129,921 |
Short Selling Information
The latest short interest is 36,204, so 0.36% of the outstanding shares have been sold short.
Short Interest | 36,204 |
Short Previous Month | 38,148 |
Short % of Shares Out | 0.36% |
Short % of Float | 0.69% |
Short Ratio (days to cover) | 0.42 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -16.67M |
Pretax Income | n/a |
Net Income | -13.37M |
EBITDA | -16.66M |
EBIT | -16.67M |
Earnings Per Share (EPS) | -$1.16 |
Full Income Statement Balance Sheet
Cash & Cash Equivalents | 11.06M |
Total Debt | n/a |
Net Cash | 11.06M |
Net Cash Per Share | $1.09 |
Equity (Book Value) | 52.14M |
Book Value Per Share | 5.14 |
Working Capital | 9.97M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$14.04 million and capital expenditures -$22,000, giving a free cash flow of -$14.06 million.
Operating Cash Flow | -14.04M |
Capital Expenditures | -22,000 |
Free Cash Flow | -14.06M |
FCF Per Share | -$1.39 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
GRCE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -34.86% |
Shareholder Yield | -34.86% |
Earnings Yield | -40.08% |
FCF Yield | -42.15% |
Analyst Forecast
The average price target for GRCE is $12.00, which is 264.74% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $12.00 |
Price Target Difference | 264.74% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -10.27% |
Stock Forecasts Stock Splits
The last stock split was on July 10, 2023. It was a reverse split with a ratio of 0.1666667:1.
Last Split Date | Jul 10, 2023 |
Split Type | Reverse |
Split Ratio | 0.1666667:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |